吸入型ZYESAMI治疗重症COVID-19,即将开展II/III期研究

2021-02-04 Allan MedSci原创

ZYESAMI™是一种合成的人血管活性肠肽(VIP)。数据表明,该药物能够保护肺泡II型细胞,这些细胞是SARS-CoV-2冠状病毒的主要靶标。

制药公司NeuroRx今天宣布,将与加利福尼亚大学尔湾分校的UCI Health合作,将研究吸入型ZYESAMI™(aviptadil)治疗重症COVID-19患者的作用(II/III期临床试验)。当前研究的目的是确定在COVID-19的早期阶段使用ZYESAMI™(aviptadil)是否可以降低因呼吸衰竭而发展为严重COVID-19的风险。呼吸衰竭是COVID-19的主要死亡原因。

ZYESAMI™是一种合成的人血管活性肠肽(VIP)。数据表明,该药物能够保护肺泡II型细胞,这些细胞是SARS-CoV-2冠状病毒的主要靶标。VIP可在实验室实验中阻止冠状病毒的复制,增加肺表面活性剂的产生并阻止病毒诱导的炎症性细胞因子的产生。

UCI肺病和危重病学部负责人Richard Lee博士说:“我们亲眼目睹了COVID-19的毁灭性,并认识到开发潜在疗法的重要性,尤其是像ZYESAMI™之类的疗法。它有望为重症COVID-19甚至更早的ICU患者提供治疗,以减少疾病进展和呼吸衰竭”。

降低COVID-19的进程可能对减轻美国的ICU和医院占用危机产生深远影响。在UCI Health所在的加利福尼亚州Orange县,目前90.0%的ICU病床和80.7%的医院病床已被占用。

 

原始出处:

https://www.firstwordpharma.com/node/1797652?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916402, encodeId=346a19164023e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Mar 05 06:21:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Oct 29 12:21:48 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924001, encodeId=045092400179, content=已读,受益匪浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Feb 10 06:33:08 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594862, encodeId=b057159486232, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 00:21:48 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922950, encodeId=c509922950a7, content=靠谱?, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 05 07:17:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922816, encodeId=592f922816a2, content=何时能彻底解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f01c2344103, createdName=1015080153, createdTime=Thu Feb 04 15:57:16 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922776, encodeId=d66e922e760b, content=血浆治疗更有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/686fa813d9f7423a8f4eb8d95ffa18dc/2e4411e44b9c4d0db82bc22975780aa8.jpg, createdBy=f18a2482420, createdName=metal分析, createdTime=Thu Feb 04 13:39:48 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-03-05 juliusluan78
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916402, encodeId=346a19164023e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Mar 05 06:21:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Oct 29 12:21:48 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924001, encodeId=045092400179, content=已读,受益匪浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Feb 10 06:33:08 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594862, encodeId=b057159486232, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 00:21:48 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922950, encodeId=c509922950a7, content=靠谱?, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 05 07:17:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922816, encodeId=592f922816a2, content=何时能彻底解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f01c2344103, createdName=1015080153, createdTime=Thu Feb 04 15:57:16 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922776, encodeId=d66e922e760b, content=血浆治疗更有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/686fa813d9f7423a8f4eb8d95ffa18dc/2e4411e44b9c4d0db82bc22975780aa8.jpg, createdBy=f18a2482420, createdName=metal分析, createdTime=Thu Feb 04 13:39:48 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1916402, encodeId=346a19164023e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Mar 05 06:21:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Oct 29 12:21:48 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924001, encodeId=045092400179, content=已读,受益匪浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Feb 10 06:33:08 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594862, encodeId=b057159486232, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 00:21:48 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922950, encodeId=c509922950a7, content=靠谱?, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 05 07:17:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922816, encodeId=592f922816a2, content=何时能彻底解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f01c2344103, createdName=1015080153, createdTime=Thu Feb 04 15:57:16 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922776, encodeId=d66e922e760b, content=血浆治疗更有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/686fa813d9f7423a8f4eb8d95ffa18dc/2e4411e44b9c4d0db82bc22975780aa8.jpg, createdBy=f18a2482420, createdName=metal分析, createdTime=Thu Feb 04 13:39:48 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-10 ms5000000518166734

    已读,受益匪浅!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1916402, encodeId=346a19164023e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Mar 05 06:21:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Oct 29 12:21:48 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924001, encodeId=045092400179, content=已读,受益匪浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Feb 10 06:33:08 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594862, encodeId=b057159486232, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 00:21:48 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922950, encodeId=c509922950a7, content=靠谱?, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 05 07:17:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922816, encodeId=592f922816a2, content=何时能彻底解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f01c2344103, createdName=1015080153, createdTime=Thu Feb 04 15:57:16 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922776, encodeId=d66e922e760b, content=血浆治疗更有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/686fa813d9f7423a8f4eb8d95ffa18dc/2e4411e44b9c4d0db82bc22975780aa8.jpg, createdBy=f18a2482420, createdName=metal分析, createdTime=Thu Feb 04 13:39:48 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1916402, encodeId=346a19164023e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Mar 05 06:21:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Oct 29 12:21:48 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924001, encodeId=045092400179, content=已读,受益匪浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Feb 10 06:33:08 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594862, encodeId=b057159486232, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 00:21:48 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922950, encodeId=c509922950a7, content=靠谱?, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 05 07:17:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922816, encodeId=592f922816a2, content=何时能彻底解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f01c2344103, createdName=1015080153, createdTime=Thu Feb 04 15:57:16 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922776, encodeId=d66e922e760b, content=血浆治疗更有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/686fa813d9f7423a8f4eb8d95ffa18dc/2e4411e44b9c4d0db82bc22975780aa8.jpg, createdBy=f18a2482420, createdName=metal分析, createdTime=Thu Feb 04 13:39:48 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-05 carrotlyl

    靠谱?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1916402, encodeId=346a19164023e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Mar 05 06:21:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Oct 29 12:21:48 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924001, encodeId=045092400179, content=已读,受益匪浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Feb 10 06:33:08 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594862, encodeId=b057159486232, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 00:21:48 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922950, encodeId=c509922950a7, content=靠谱?, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 05 07:17:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922816, encodeId=592f922816a2, content=何时能彻底解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f01c2344103, createdName=1015080153, createdTime=Thu Feb 04 15:57:16 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922776, encodeId=d66e922e760b, content=血浆治疗更有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/686fa813d9f7423a8f4eb8d95ffa18dc/2e4411e44b9c4d0db82bc22975780aa8.jpg, createdBy=f18a2482420, createdName=metal分析, createdTime=Thu Feb 04 13:39:48 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-04 1015080153

    何时能彻底解决

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1916402, encodeId=346a19164023e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Mar 05 06:21:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Oct 29 12:21:48 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924001, encodeId=045092400179, content=已读,受益匪浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Feb 10 06:33:08 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594862, encodeId=b057159486232, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 00:21:48 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922950, encodeId=c509922950a7, content=靠谱?, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 05 07:17:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922816, encodeId=592f922816a2, content=何时能彻底解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f01c2344103, createdName=1015080153, createdTime=Thu Feb 04 15:57:16 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922776, encodeId=d66e922e760b, content=血浆治疗更有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/686fa813d9f7423a8f4eb8d95ffa18dc/2e4411e44b9c4d0db82bc22975780aa8.jpg, createdBy=f18a2482420, createdName=metal分析, createdTime=Thu Feb 04 13:39:48 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-04 metal分析

    血浆治疗更有效!

    0

相关资讯

Clin Trans Gastroenterology:粪便中新蝶呤水平可以预测COVID-19患者胃肠道症状的发生率

新冠病毒在全球已经流行一段时间了,患有新冠病毒的患者多达50%还具有胃肠道(GI)症状,例如腹泻,呕吐或恶心。

JAMA Netw Open:COVID-19患者出院后不仅运动耐量降低,心理也受到创伤!

目前,新冠肺炎(COVID-19)仍在全球肆虐,据数据显示,全球已确诊超1亿258万,累计死亡人数超221.4万。

Lenzilumab治疗COVID-19住院患者,即将开展III期临床

生物制药公司Humanigen近日宣布,已完成Lenzilumab治疗COVID-19住院患者的III期研究入组工作。该公司预计将于2021年3月公布主要临床数据。

英国将在全球范围内提供基因组学专业知识,以识别新的COVID-19变体

英国政府宣布,英国将向国际社会提供基因组学专业知识,以帮助鉴定COVID-19的新变种。

Brilacidin治疗COVID-19的II期临床试验,计划于下周开始

临床阶段生物制药公司Innovation Pharmaceuticals近日宣布,该公司用于治疗COVID-19的Brilacidin的II期临床试验计划于下周开始。

COVID-19可能会引起睾丸损伤,影响男性生殖能力!

新冠肺炎(COVID-19)仍在全球肆虐,据数据显示,全球确诊超1亿308万,累计死亡病例超222.7万例。

拓展阅读

Cureus:2型糖尿病状态、糖尿病并发症严重程度指数评分及其与COVID-19严重程度的关系

与非糖尿病患者相比,我们样本中的糖尿病患者发生COVID-19不良临床结果和住院死亡率的几率更高。

Lancet Infect Dis:口服VV116用于治疗轻中度COVID-19成人患者的有效性和安全性评价

目前,治疗COVID-19的医疗需求仍未得到满足,新型抗病毒药物-VV116可用于治疗轻中度COVID-19成人患者,能够显著缩短临床症状持续时间,与其他药物较少发生药物间相互作用,且安全性良好。

论文解读|Yihua Wang教授团队新研究揭示了揭示COVID-19对肺癌治疗和研究的深远影响

该文章揭示了此次大流行对肺癌治疗、临床试验、研究活动的影响。

JAMA Intern Med:COVID-19相关急性肾损伤与长期肾脏结果

与患有其他疾病相关AKI的患者相比,COVID-AKI住院幸存者的MAKE发生率、长期肾功能下降和死亡率均显著较低。

【解读分享】2024 PIDS共识声明:儿童和青少年COVID-19预防和管理指南

本文主要针对儿童和青少年COVID-19预防和管理提供指导建议,涉及COVID-19的危险分层、治疗和预防,点击即可下载查看。

呼吸治疗师在抗击 COVID-19 中的作用

我们的呼吸治疗师通过提供氧气、分析血气、参与插管、管理呼吸机、以及参与急危重症患者院内外转运等工作,以各种方式接触到每一位患者。